INTRODUCTION
============

Genome-wide association studies (GWAS) are an important approach for identifying genetic variants associated with complex human diseases. Recently, meta-analysis of GWAS has been used to obtain collective evidence from the multiple GWAS studies ([@B15]; [@B7]; [@B29]; [@B13]; [@B12]; [@B26]; [@B28]; [@B19]; [@B23]). Unfortunately population stratification in the studied samples can lead to spurious associations in disease studies ([@B2]; [@B6]; [@B17]; [@B20]). To control the spurious associations caused by population stratification in meta-analysis of GWAS, genomic control (GC) correction within each study (which is referred to as single GC correction) has been used ([@B4]; [@B5]; [@B24]; [@B3]; [@B13]). However, the GC correction method cannot effectively control false positive rates and may lead to a loss in power ([@B20]; [@B16]; [@B28]). Therefore, a double GC correction method has been proposed and implemented in the widely used meta-analysis software METAL and GWAMA ([@B16]; [@B28]). The double GC correction method adjusts the set of test statistics across all markers within each study by a GC inflation factor, calculates a combined statistic across studies at each marker, and then adjusts all combined statistics across the genome by the corresponding GC inflation factor. The double GC correction method has been used by many investigators in their meta-analyses (e.g., [@B13]; [@B16]; [@B28]; [@B11]). To adjust for stratification in meta-analysis of GWAS, another popular approach is the principal component analysis (PCA) correction method that adjusts for stratification by top principal components (PCs) of genotype data within each study ([@B20]; [@B27]; [@B23]).

In this research, we compared the single GC correction, the double GC correction and PCA correction in meta-analysis by simulation studies and applied these methods to a meta-analysis of two real data sets from the Atherosclerosis Risk in Communities (ARIC) project and the Multi-Ethnic Study of Atherosclerosis (MESA) project. Results from simulations and real data analysis suggest that when population stratification exists, using double GC correction can have inflated false positive error rates at markers with significant allele frequency differentiation in the subpopulations (such as caused by recent strong selection), and can have lower power than using the PCA method for stratification correction in meta-analysis.

MATERIALS AND METHODS {#s1}
---------------------

We consider *K* case--control studies with *n*~k~ individuals in the *k*^*th*^ study (*k* = 1,2,...,*K*) and *N* single nucleotide polymorphisms (SNPs) in each study. In the *k*^*th*^ study, let *Y*~ik~ denote the disease status (1 = disease, 0 = no disease) of the *i*^*th*^ individual, let *g*~ijk~ denote the additive genotype coding value (the count of reference alleles) at the *j*^*th*^ SNP of *i*^*th*^ individual (*j* = 1,2,...,*N*,*i* = 1,2,...,*n*~k~), and let ***X*~*ik*~** = (*x*~1k~,*x*~2~~k~,...,*x*~sk~)^T^ denote a vector of *s* covariates.

In this research, we focus on fixed-effect meta-analysis, i.e., we assume that the allelic effects at a test marker are the same across all studies. In the *k*^th^ study, we use the following logistic regression model
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where α~0k~ is the study-specific intercept, **α~*k*~** is the coefficient vector corresponding to covariate vector ***X*~*ik*~**, and β~*kj*~ denote the genetic effect (log odds ratio) of the reference allele at the *j*^*th*^ SNP in the *k*^*th*^ study. We can estimate β~kj~ and var(β~kj~) at the *j*^*th*^ SNP based on the logistic model (Eq. 1). Thus, the combined allelic effect *B*~j~ at the *j*^*th*^ SNP across *K* studies, can be calculated as
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where *w*~*kj*~ is a weight for the genetic effect $\hat{\beta_{kj}}$ and $w_{kj} = \left\lbrack {\hat{var}\left( \hat{\beta_{kj}} \right)} \right\rbrack^{- 1}$ is the inverse of the variance of the estimated allelic effect in the *k*^*th*^ study. The variance of *B*~j~ is estimated by $\left( {\Sigma_{k = 1}^{K}w_{kj}} \right)^{- 1}$ and its estimated standard error SE~j~ is the square root of variance *V*~j~, i.e., ${SE_{j}} = \sqrt{V_{j}}$. Therefore, the combined statistic $\chi_{j}^{2} = {B_{j}^{2}/V_{j}}$ has an approximate χ^2^ distribution with one degree of freedom ([@B16]; [@B28]).

GC CORRECTION IN META-ANALYSIS
------------------------------

To adjust for population stratification, in the *k*^*th*^ study, we can calculate the statistic $\chi_{kj}^{2}\left( {{\hat{\beta_{kj}}/S}E_{kj}} \right)^{2}$ at the *j*^*th*^ SNP (*j* = 1,2,,...,*N*), and then calculate a GC inflation factor λ~*k*~ that is the median of these statistics $\chi_{kj}^{2}\left( j = 1,2,\ldots,N \right)$ divided by its expectation under the null hypothesis of no association, which is 0.455 ([@B4]). To adjust for stratification within each study in the meta-analysis, we can calculate a corrected weight at the *j*^*th*^ SNP in the *k*^*th*^ study as $w_{kj}^{\prime} = {w_{kj}/\lambda_{k}}$ (see also Section "Materials and Methods" for the calculation of *w*~*kj*~) and calculate the combined allelic effect *B*~j~ by using $w_{kj}^{\prime}$ to replace *w*~kj~ in Eq. 2 correspondingly, the variance of *B*~j~ can be calculated as $V_{j} = \left( {\Sigma_{k = 1}^{K}w_{kj}^{\prime}} \right)^{- 1}$. The combined statistic $\chi_{j}^{2} = {B_{j}^{2}/V_{j}}$ can be calculated for meta-analysis (*j* = 1,2,...,*N*).

DOUBLE GC CORRECTION IN META-ANALYSIS
-------------------------------------

After GC correction in each individual study as described above, the combined statistics $\chi_{j}^{2}\left( j = 1,2,\ldots,N \right)$ may still have over-dispersion which is caused by population stratification. Therefore, investigators proposed to further adjust the combined statistics $\chi_{j}^{2}$ by the corresponding GC inflation factor λ, which is the median of the combined statistics $\chi_{j}^{2}$ divided by 0.455 ([@B16]; [@B28]). This process corrects for stratification twice and is called double GC correction.

PCA CORRECTION IN META-ANALYSIS
-------------------------------

[@B20] proposed to correct for stratification by PCA in GWAS analysis. For meta-analysis of GWAS with *K* (\>1) case--control studies of population stratification, PCA has been used to correct for stratification within each of the *K* studies ([@B23]): for each of the *K* studies, we can calculate the PCs ([@B8]) of genome-wide genotype values for each individual and use the top 10 PCs as covariates, as suggested in the literature ([@B20]; [@B14]; [@B23]), to correct for population stratification by incorporating these covariates (top 10 PCs) into the logistic regression model (Eq. 1). Meta-analysis for the *K* studies can be conducted based on this modified model.

SIMULATION STUDIES
==================

DATA SIMULATION
---------------

To evaluate the performance of the single GC correction, double GC correction, and PCA correction in meta-analysis of data with population stratification, we simulated datasets on *K* case--control studies in a similar way to those described in [@B22] and [@B20]. Individuals in each of the *K* case--control studies were sampled from two populations. For each dataset we simulated 100,000 independent random SNPs. To generate each of these SNPs, we used the Balding--Nichols model with *F*~ST~ = 0.01 ([@B1]) to generate allele frequencies *f*~s~ for populations *s*(*s* = 1, 2) which was drawn from a beta distribution with parameters *f*~s~(1 - *F*~st~)/*F*~st~ and (1 - *f*~s~) (1 - *F*~st~)/*F*~st~. *F*~ST~ = 0.01 usually leads to allele frequency differences under 0.10 for typical common SNPs ([@B20]). At each of the random SNPs, we assumed Hardy--Weinberg equilibrium in each population, and individuals from populations were assigned genotypic values of 0, 1, or 2 with probabilities $\left( {1 - f_{s}} \right)^{2},{2{f_{s}\left( {1 - f_{s}} \right)}},\text{or}f_{s}^{2}$, respectively. For the PCA correction, we used these 100,000 random SNPs to calculate the first 10 PCs, which were used as covariates in the analysis.

### Meta-analysis with two case--control studies (K = 2)

We first simulated two case--control studies. In each study, 60% of the cases and 40% of the controls were sampled from population 1 and the remaining cases and controls from population 2.

### Meta-analysis with K = 5 case--control studies

To evaluate the performance of the three correction methods in meta-analysis with *K* (\>2) studies, we simulated datasets on five case--control studies. Each of the five studies had 1000 cases and 1000 controls. For each case--control study, a proportion of cases and a proportion of controls were sampled from population 1, and the remaining cases and controls were sampled from the population 2: in the first study, 55% of the cases and 45% of the controls were sampled from population 1; in the second study, 70% of the cases and 30% of the controls; in the third study, 60% of the cases and 40% of the controls; in the fourth study, 70% of the cases and 30% of controls; in the fifth study, 60% of the cases and 40% of the controls.

TYPE I ERROR RATE EVALUATION
----------------------------

To verify the effectiveness of the three stratification correction methods in meta-analysis, we simulated replicated data sets. Each data set contained 100,000 independent random SNPs (as described above) and an additional test SNP (which is not associated with the disease). We simulated the test SNP by the following four scenarios: in the first scenario, the test SNP was simulated in each individual by the same way as that for the random SNPs described above using the Balding--Nichols model with *F*~ST~ = 0.01; for the second, third, and fourth scenarios, we assumed that the test SNP had significant different allele frequencies in populations 1 and 2, which could be caused by recent strong selection (see also [@B20]). In scenario 2, the frequencies in populations 1 and 2 were 0.4 and 0.2, respectively; in scenario 3, frequencies were 0.6 and 0.2; in scenario 4, frequencies were 0.8 and 0.2. For each scenario, we computed type I error rates of meta-analysis using the three correction methods (PCA, single GC correction, and double GC correction) separately, under a set of combination of parameters (numbers of cases and controls in the two studies). For each combination of these parameters, we simulated 10^8^ replicated data sets to estimate the type I error rates at significance levels of 10^--5^ and 10^--6^. We did not use the significance level of 10^--7^ because estimating accurate type I error rates at this level requires at least 10^9^ replicated data sets. This is computationally intensive.

### Type I error rates for meta-analysis with two case--control studies (K = 2)

Detailed results are listed in **Table [1](#T1){ref-type="table"}**, which shows that using PCA correction can control the type I error rates well. However, using the single GC correction or double GC correction, the type I error rates could be controlled only in the first scenario in which the test SNP was randomly generated with no association with disease. For other three scenarios in which populations 1 and 2 had significant different allele frequencies at the test SNPs, both single GC correction and double GC correction had inflated type I error rates; the type I error rates could increase to almost 1 when the allele frequency differences between populations 1 and 2 increased. For example, when both studies had 1000 cases and 1000 controls, the populations 1 and 2 had allele frequencies of 0.6 and 0.2 at the test SNP, respectively, and the nominal significance level was 10^--6^, the type I error rates of meta-analysis using the PCA correction, single GC correction, and double GC correction were 7.70 × 10^--7^, 0.585, and 0.591, respectively.

###### 

Type I error rates of meta-analysis with two case--control studies for different allele frequencies in the two subpopulations.

  Frequency^[1](#T1fn01){ref-type="fn"}^   Study 1^[2](#T1fn02){ref-type="fn"}^   Study 2   10^−5^   10^−6^                                                                                       
  ---------------------------------------- -------------------------------------- --------- -------- -------- --------------------------------------- ---------- ---------- ---------- ---------- ----------
  Ran(ran)^[3](#T1fn03){ref-type="fn"}^    1000                                   1000      1000     1000     9.51e--6^[4](#T1fn04){ref-type="fn"}^   5.05e--6   5.34e--6   1.07e--6   3.90e--7   3.80e--7
                                           1500                                   1500      500      500      9.88e--6                                5.00e--6   5.29e--6   9.19e--7   3.90e--7   4.60e--7
                                           750                                    1500      1500     750      1.04e--5                                5.08e--6   5.50e--6   8.50e--7   5.20e--7   5.70e--7
  0.4 (0.2)                                1000                                   1000      1000     1000     9.89e--6                                1.25e--2   1.31e--2   9.20e--7   1.75e--3   1.86e--3
                                           1500                                   1500      500      500      1.01e--5                                8.04e--3   8.49e--3   1.01e--6   9.77e--4   1.05e--3
                                           750                                    1500      1500     750      1.02e--5                                1.26e--2   1.30e--2   1.03e--6   1.76e--3   1.85e--3
  0.6 (0.2)                                1000                                   1000      1000     1000     9.67e--6                                0.836      0.839      7.70e--7   0.585      0.591
                                           1500                                   1500      500      500      9.43e--6                                0.763      0.769      8.60e--7   0.478      0.486
                                           750                                    1500      1500     750      9.86e--6                                0.837      0.841      9.30e--7   0.588      0.594
  0.8 (0.2)                                1000                                   1000      1000     1000     9.98e--6                                1.00       1.00       1.11e--6   1.00       1.00
                                           1500                                   1500      500      500      9.61e--6                                1.00       1.00       9.50e--7   1.00       1.00
                                           750                                    1500      1500     750      9.69e--6                                1.00       1.00       9.20e--7   1.00       1.00

Allele frequencies in the two subpopulations from which cases and controls were sampled for each study.

Sample size.

Allele frequencies in the two populations of each study were randomly generated.

9.51e-6 = 9.51 × 10^−6^

### Type I error rates for meta-analysis with five case--control studies (**K** = 5)

We estimated the type I error rates for meta-analysis with *K* = 5 case--control studies. The detailed results are shown in **Table [2](#T2){ref-type="table"}**. We can see the type I error rates had similar pattern to that for meta-analysis with two case--control studies described above.

###### 

Type I error rates of meta-analysis with five studies for different allele frequencies in the two subpopulations.

  Frequency   10^−5^     10^−6^                                      
  ----------- ---------- ---------- ---------- ---------- ---------- ----------
  Ran(ran)    9.89e--6   7.48e--6   8.13e--6   1.04e--6   6.30e--7   7.20e--7
  0.4 (0.2)   1.00e--5   0.418      0.426      9.90e--7   0.195      0.203
  0.6 (0.2)   1.01e--5   1.00       1.00       1.03e--6   0.999      1.00
  0.8 (0.2)   1.01e--5   1.00       1.00       9.78e--7   1.00       1.00

POWER EVALUATION
----------------

To evaluate power of meta-analysis using the three stratification correction methods, we simulated 10,000 replicated datasets. Each data set contained 100,000 independent random SNPs (described above) and a causal SNP. We simulated the causal SNP by a similar method of [@B20]. We used the Balding--Nichols model with *F*~ST~ = 0.01 again to generate allele frequencies for populations 1 and 2. We generated genotypes at the causal SNP by using a multiplicative disease risk model with a relative risk (*R*) for the causal allele as follows: genotypic values of control individuals were generated as those for random SNPs described above. Case individuals were assigned genotypic values 0,1, or 2 with relative probabilities (1 + *f*~s~)^2^/*S*, 2*Rf*~s~(1 - *f*~s~)/*S*, or R^2^ f~s~^2^ /S, respectively, where *S* = (1 - *f*~s~)^2^ + 2*Rf*~s~(1 - *f*~s~) + R^2^ f~s~^2^ . The power of meta-analysis was estimated based on 10,000 replicated datasets at significance levels of 10^--5^, 10^--6^, and 10^--7^, respectively.

### Power evaluation for meta-analysis with two case--control studies (K = 2)

We considered various numbers of cases and controls and a set of relative risk values (*R* = 1.2, 1.3, 1.4, 1.5) at the causal SNP in the two studies. The results are summarized in **Table [3](#T3){ref-type="table"}**. The power of meta-analysis using PCA correction is much higher than both that using single GC correction and that using double GC correction. For example, when *R*s in the two studies were 1.3 and 1.4 and both studies had 1000 cases and 1000 controls, the power of meta-analyses using PCA correction, single GC correction, and double GC correction were 0.6386, 0.1709, and 0.18, respectively, at the significance level of 10^--7^.

###### 

Power of meta-analysis of GWAS for two studies using PCA correction, single GC correction (1 GC), and double GC correction (2 GC) at significance levels of 10^--5^, 10^--6^, and 10^--7^

  Study 1   Study 2    10^--5^    10^--6^   10^--7^                                                                                                   
  --------- ---------- ---------- --------- ---------- ---------- ------------ -------- -------- ------------ -------- -------- ------------ -------- --------
  **1.2**   **1000**   **1000**   **1.2**   **1000**   **1000**   **0.1901**   0.0402   0.0425   **0.0908**   0.0113   0.0124   **0.0384**   0.0041   0.0045
            **1000**   **1000**   **1.3**   **1000**   **1000**   **0.4449**   0.1207   0.1194   **0.2797**   0.0511   0.0502   **0.1637**   0.0199   0.0196
            **1500**   **1500**   **1.4**   **500**    **500**    **0.4232**   0.1368   0.1450   **0.2631**   0.0604   0.0645   **0.1437**   0.0238   0.0253
            **1500**   **750**    **1.5**   **750**    **1500**   **0.8332**   0.4306   0.4368   **0.7221**   0.2724   0.2787   **0.5959**   0.1549   0.1602
  **1.3**   **1500**   **1500**   **1.3**   **500**    **500**    **0.7029**   0.2412   0.2375   **0.5487**   0.1228   0.1205   **0.3934**   0.0552   0.0535
            **1000**   **1000**   **1.4**   **1000**   **1000**   **0.8768**   0.4703   0.4806   **0.7738**   0.3003   0.3085   **0.6386**   0.1709   0.1800
            **1000**   **1000**   **1.5**   **1000**   **1000**   **0.9425**   0.6377   0.6403   **0.8835**   0.4683   0.4702   **0.8060**   0.3128   0.3152
  **1.4**   **750**    **1500**   **1.4**   **1500**   **750**    **0.9551**   0.6532   0.6570   **0.9046**   0.4740   0.4782   **0.8251**   0.3190   0.3215
            **1500**   **1500**   **1.5**   **500**    **500**    **0.9700**   0.7008   0.6986   **0.9302**   0.5442   0.5400   **0.8733**   0.3819   0.3773
  **1.5**   **1500**   **750**    **1.5**   **750**    **1500**   **0.9952**   0.8942   0.8930   **0.9842**   0.8044   0.8028   **0.9686**   0.6844   0.6824

Boldface values denote the highest power among meta-analyses using the three methods (PCA, 1 GC, and 2 GC).

### Power evaluation meta-analysis with five case--control studies (K = 5)

For the meta-analysis with five case--control studies, we only considered eight combined relative risk values (see **Table [4](#T4){ref-type="table"}**). Each of the five studies has 1000 cases and 1000 controls. The results from five case--control studies also demonstrated the power of meta-analysis using PCA correction is the highest among the meta-analysis using the three correction methods.

###### 

Power of meta-analysis of GWAS for five studies using PCA correction, single GC correction (1 GC), and double GC correction (2 GC) at significance levels of 10^−5^, 10^−6^, and 10^−7^.

  *R*   10^--5^   10^--6^   10^--7^                                                                                 
  ----- --------- --------- --------- ----- -------- -------- -------- -------- -------- -------- -------- -------- --------
  1.2   1.2       1.2       1.2       1.2   0.8284   0.3120   0.3148   0.6912   0.1683   0.1703   0.5421   0.0823   0.0841
  1.3   1.3       1.3       1.3       1.3   0.9985   0.8735   0.8796   0.9937   0.7586   0.7670   0.9873   0.6101   0.6226
  1.4   1.4       1.4       1.4       1.4   1.000    0.9951   0.9951   1.000    0.9828   0.9832   1.000    0.9539   0.9545
  1.5   1.5       1.5       1.5       1.5   1.000    0.9997   0.9997   1.000    0.9991   0.9991   1.000    0.9978   0.9979
  1.2   1.2       1.3       1.3       1.4   0.9940   0.7678   0.7779   0.9829   0.6153   0.6310   0.9592   0.4549   0.4693
  1.3   1.3       1.4       1.4       1.5   0.9998   0.9843   0.9854   0.9998   0.9598   0.9625   0.9996   0.9164   0.9202
  1.3   1.4       1.4       1.5       1.5   1.000    0.9928   0.9931   1.000    0.9772   0.9783   1.000    0.9453   0.9472
  1.2   1.2       1.4       1.4       1.5   0.9997   0.9267   0.9299   0.9985   0.8498   0.8560   0.9960   0.7414   0.7514

ANALYSES OF TWO REAL DATA SETS
==============================

We performed meta-analysis of GWAS for two real data sets on European Americans drew from the ARIC and the MESA projects. We chose hypertension as phenotype and gender, age, body mass index, waist circumference, and smoking status as covariates in the logistic regression model (Eq. 1). There were 9,526 subjects with 839,173 SNPs in ARIC project and 2,397 subjects with 577,627 SNPs in MESA project. We first extracted 414,363 SNPs with minor allele frequency ≥0.05 and shared by the two data sets, and focused our analyses on these SNPs. Among these 414,363 SNPs, 3,295 SNPs were not concordant in terms of positive or negative strand in the two data sets. So we flipped the strands for these SNPs in MESA. In our research, an individual was defined with hypertension if systolic blood pressure ≥140 mm Hg, diastolic blood pressure ≥90 mm Hg, a self-reported history of hypertension or current use of antihypertensive medications ([@B25]; [@B10]; [@B18]). We removed the subjects with missing phenotypes and multiple copies of the same subject from ARIC and MESA datasets and excluded 212 subjects as outliers from ARIC and 19 subjects as outliers from MESA if at least one of the first 10 PCs of the subject is out of the interval \[μ − 6σ,μ + 6σ\], where μ and σ are the mean and standard deviation of a PC, respectively. Finally, there were 2,780 cases and 5,881 controls left in ARIC with GC inflation factor λ = 1.04967 and 920 cases and 1458 controls left in MESA with λ = 1.07127. As an ancillary illustration of population stratification in the two data sets, we plotted the first two PCs of all subjects in each data set (as shown in **Figure [1](#F1){ref-type="fig"}**). The figure indicates that there is stratification in these two data sets. In the data analysis, genotype coding value at each SNP was defined as the count of the reference allele.

![**The stratification structure plotted by the first PC versus the second PC for the two data sets ARIC (A) and MESA (B)**.](fgene-03-00300-g001){#F1}

In meta-analyses of GWAS for the two real data sets, we used PCA correction, single GC correction, and double GC correction for the stratification, separately. The top eight SNPs with *p*-values \<10^--5^ in at least one of the three meta-analysis methods are displayed in **Table [5](#T5){ref-type="table"}**. At each of the eight SNPs, meta-analysis with PCA correction had much smaller *p*-value than that with double GC. This may indicate that meta-analysis with double GC correction for stratification is not as effective as that with PCA.

###### 

Top SNPs with *p*-values \<10^−5^ in a meta-analysis with PCA correction, single GC correction (1 GC), or double GC correction (2 GC).

  Chromo-some   SNP          Reference allele   *p*-Value              
  ------------- ------------ ------------------ ----------- ---------- ----------
  1             rs6688672    T                  6.63e--6    1.25e--5   1.35e--5
  1             rs6657751    G                  3.46e--6    6.40e--6   6.94e--6
  1             rs10493964   C                  6.64e--6    1.17e--5   1.27e--5
  4             rs7673213    G                  4.06e--6    9.20e--6   9.95e--6
  4             rs3762865    A                  8.44e--6    1.80e--5   1.94e--5
  5             rs1477654    A                  7.29e--6    7.82e--6   8.47e--6
  9             rs10960562   A                  4.07e--6    1.82e--5   1.96e--5
  9             rs10960592   T                  5.50e--6    2.13e--5   2.29e--5

DISCUSSION
==========

In this research, we evaluated the performance of three methods for correcting for population stratification (PCA correction, single GC correction, and double GC correction) in meta-analysis of GWAS by simulation studies. Our results demonstrate that both the single GC correction and the widely used double correction cannot control type I error rates in meta-analysis, when the test SNP has significant allele frequency differentiation in the subpopulations in the case--control data. On the other hand, the PCA correction can control type I error rates well. In addition, when population stratification exists in the case--control data, using double GC method usually results in much lower power than using the PCA correction in meta-analysis, even though the casual SNP does not have significant allele frequency differentiation in the subpopulations. We note that [@B20] reported similar results in single GWAS analysis. Therefore, the double GC method is not effective to correct for stratification in meta-analysis.

Although the PCA correction method works well for correction for stratification in meta-analysis, it may need more than 5,000 SNPs to calculate PCs for each individual ([@B20]). This may be challenging in replication studies with meta-analysis in which usually only a small set of significant SNPs identified from previous meta-analysis are collected and tested. If population stratification exists in the data for replication meta-analysis, we would suggest collecting additional 5,000 or 10,000 independent SNPs to calculated PCs for each individual, and use these PCs to correct for population stratification when testing the small set of promising SNPs identified from previous meta-analysis. As can be seen from the results described above, using PCA correction controls type I error rates well, and more importantly can have increased power in meta-analysis compared to the widely used double GC correction.

When evaluating the three methods for correcting for stratification in meta-analysis for case--control studies, we only considered the fixed-effect model and the additive genetic model for case--control designs with binary traits. We expect that the conclusion will also hold for quantitative traits. We plan to consider random-effects model in meta-analysis and the dominant, recessive genetic models for evaluating the three methods for population stratification correction used in meta-analysis in our future study.

In our simulation studies, we did consider cryptic relatedness among individuals. Since GC method can be useful for controlling spurious association caused by relatedness in the data, investigators proposed a "PCA + double GC" method to control the spurious association findings in meta-analysis as follows: 1 to perform PCA adjustment for population stratification in the individual study association analysis, followed by a GC correction on the genome-wide results, 2 to perform a GC correction on the combined statistics over all studies by the corresponding GC inflation factor λ (see Materials and Methods). Although this "PCA + double GC" method may control type I error rate well, it may not maximize power to detect true associations in meta-analysis ([@B21]). To adjust for the cryptic relatedness and population stratification in meta-analysis, a better choice may be using the mixed model approaches, such as the EMMAX and TASSEL software ([@B9]; [@B30]).
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